SRPT Stock - Sarepta Therapeutics, Inc.
Unlock GoAI Insights for SRPT
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.90B | $1.24B | $933.01M | $701.89M | $540.10M |
| Gross Profit | $1.58B | $1.09B | $793.02M | $604.84M | $476.72M |
| Gross Margin | 83.2% | 87.9% | 85.0% | 86.2% | 88.3% |
| Operating Income | $218.08M | $-267,824,000 | $-536,201,000 | $-459,710,000 | $-564,163,000 |
| Net Income | $235.24M | $-535,977,000 | $-703,488,000 | $-418,780,000 | $-554,128,000 |
| Net Margin | 12.4% | -43.1% | -75.4% | -59.7% | -102.6% |
| EPS | $2.47 | $-5.80 | $-8.03 | $-5.15 | $-7.11 |
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping. The company is also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteEarnings History & Surprises
SRPTEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-0.97 | — | — | — |
Q4 2025 | Nov 3, 2025 | $0.01 | $-0.13 | -1400.0% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $1.11 | $2.02 | +82.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $0.35 | $-3.42 | -1077.1% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $1.38 | $1.50 | +8.7% | ✓ BEAT |
Q4 2024 | Nov 6, 2024 | $-0.06 | $0.62 | +1139.7% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $0.01 | $0.07 | +1201.1% | ✓ BEAT |
Q2 2024 | May 1, 2024 | $0.10 | $0.73 | +625.6% | ✓ BEAT |
Q1 2024 | Feb 28, 2024 | $0.01 | $0.47 | +3084.3% | ✓ BEAT |
Q4 2023 | Nov 1, 2023 | $-1.66 | $-0.46 | +72.3% | ✓ BEAT |
Q3 2023 | Aug 2, 2023 | $-1.89 | $-0.27 | +85.7% | ✓ BEAT |
Q2 2023 | May 2, 2023 | $-1.46 | $-0.97 | +33.6% | ✓ BEAT |
Q1 2023 | Feb 28, 2023 | $-1.28 | $-1.24 | +3.1% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-1.21 | $-2.94 | -143.0% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-1.07 | $-2.65 | -147.7% | ✗ MISS |
Q2 2022 | May 4, 2022 | $-1.35 | $-1.20 | +11.1% | ✓ BEAT |
Q1 2022 | Mar 1, 2022 | $-1.51 | $-1.42 | +6.0% | ✓ BEAT |
Q4 2021 | Nov 3, 2021 | $-1.86 | $-0.60 | +67.7% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-1.03 | $-1.02 | +1.0% | ✓ BEAT |
Latest News
Frequently Asked Questions about SRPT
What is SRPT's current stock price?
What is the analyst price target for SRPT?
What sector is Sarepta Therapeutics, Inc. in?
What is SRPT's market cap?
Does SRPT pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to SRPT for comparison